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present study two asymptomatie haemophiliacs who sub-
sequently developed AIDS had antibodies to HTLV-III. 
The observation that the proportion of asymptomatic 
haemophiliaes with antibodies to HTLV-III may have increased 
from 1983 to 1984 deserves further study using sequential 
sampIes from the same individuals. As the ineubation period 
for the development of AIDS following blood transfusion has 
been estimated to range from 10 months to 4 yr26, further studies 
are needed to evaluate the impact of this observation. Antibody 
positivity seems to be an indieator of viral infection in most 
healthy and leukaemic individuals who were naturally exposed 
to HTLV.127-29 as weil as in AIDS patients and healthy male 
hornosexuals exposed to HTLV-III I - 4 • However, it is possible 
that a significant proportion of asymptomatie haemophiliaes 
might be exposed only to inaetivated HTLV-1I1 rather than to 
live virus, owing to the manufacturing process involved in the 
preparation of commercial factor VIII concentrate. In addition, 
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Interstitial pneumonia linked with reaetivation of latent human 
cytomegalovirus due to iatrogenie immunosuppression ean be a 
serious eomplieation of bone marrow transplantation therapy of 
aplastie anaemia and aeute leukaemia l • Cellular immunity plays 
a eritieal role in the immune sunreillanee of inapparent 
cytomegalovirus infections in man and the mousel - 7 • The molecular 
basis of lateney, however, and tbe interaction between latently or 
recurrently infeeted eells and the immune system of the host are 
poorfy understood. We have detected aso far unknown antigen in 
the mouse model, This antigen is found in infeeted eells in assoei-
alloD with the expression of the herpesvirus 'immediate early' 
genes and is reeognized by eytolytic T lymphoeytes (CTL)8. We 
now demonstrate that an unexpeetedly high proportion of the CTL 
preeursors genera ted in vivo during aeute murine eytomegalovirus 
infeetion are specifie for eells that seleetively synthesize immediate 
early proteins, indieating an immunodominant role of viral non-
struetural proteins. 
Aceording to the static state hypothesis of latencl, it is 
assumed that viral progeny are not produeed because the tran-
scription process ofthe virus is interrupted reversibly at an early 
stage in the cyc\e of virus multiplication. In herpes virus infec-
ti ans of permissive cells in vitro, analysed in detail for herpes 
simplex viruses 10,11, viral protein synthesis is eoordinately regu-
lated and starts with the expression of the 'immediate early' 
(IE) genes, which are transcribed by host RNA polymerase 11. 
The IE proteins exert important control funetions as exemplified 
by their ability to act as transcriptional activators l2,13 and they 
need to be present throughout the replication eycle of herpes-
it is c\ear that those individuals exposed to factor IX prepar-
ations are also at risk for the development of antibodies to 
HTLV-III_ Further studies are needed to determine wh ether the 
presence of antibodies to HTLV-III indicates immunization, 
infection or an asymptomatic carrier state. In addition, the 
relationship between HTLV-I11 seropositivity and immuno-
logical dysfunction, which has been shown to be widespread 
among apparently healthy haemophiliacs30,31, requires investi-
gation. 
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Table 1 Determination of the IL-CTLp frequency by LDCC 
No. of IL-CTLp 
Dose of lectin IL-CTLp per 106 Iymphocytes 
( .... gmr') frequency (95% confidence limits) pMC* 
ConA 5 1/5,900 171 (126-215) 0.23 
10 1/2,800 359 (217-502) 0.11 
20 1/2,600 383 (270-495) 0.50 
PHA 5 1/5,600 179 (124-234) 0.24 
10 1/9,500 105 (71-140) 0.52 
20 1/7,600 132 (93-171) 0.24 
BALB/ c (H_2 d haplotype) mice were infected at the left hind footpad 
with 105 PFU of tissue-culture propagated MCMV (ATCC VR-194 
Smith strain) and 8 days later Iymphoeytes derived from the draining 
popliteal Iymph nodes were tested for the frequency of activated CTLp 
in a Iimiting dilution assay20. In brief, graded numbers of Iymphocytes 
were cuItivated for 6 days in 96-well round-bottomed microtitre plates 
with no addition ofviral antigen using medium MEM-a (Gibco) supple-
mented with 10% vol. fetal ealf serum and 20% vol. interleukin-2 
containing supernatant. Starting the dilution series with I x 105 Iym-
phoeytes, 7 log2 dilution steps were performed with 24 replicate micro-
cultures each. To detect all CTL clones irrespective of their antigen-
specificity, the LDCC assay was applied. Various doses of the lectins 
Con A (Pharmacia) or PHA (Flow Laboratories) were added to 103 
sICr-Iabelled, noninfected MEF and CTL at the b~ginning ofa standard 
3-h SICr release assay. Precursor frequencies were estimated from the 
proportion of nonresponding microcultures using the minimum X2 
(MC)32 and maximum likelihood (ML)33 methods. Only the results of 
the MC evaluation are shown. 
.. Probability calculated by MC method. Aecording to the proposition 
of Taswell32 an estimate was accepted for a probability of P> 0.05 and 
a ML-MC deviation of < 10%. 
viruses to perrnit transcription of the 'early' and 'Iate' genes l4. 
Interferenee with viral transcription at the stage ofthe expression 
of IE genes may be involved in establishing virallatency; hence 
many eHorts have been made to clone and map the IE regions 
of herpesvirus genomes, inc\uding those of human l5,16 and 
murine eytomegalovirus (MCMV)'7-19. In partieular, re-
expression of IE genes must be one of the first events in virus 
reactivation from latency. Seleetive synthesis of JE proteins leads 
©          Nature Publishing Group1984
~37~O-------------------------------------LETTERSTONATURE--------------~N~A~T~U~R~E~V~O~L.~3~12~22~N~O~V~E=M~BE=R~19~84 
-o 
c: 
2 
E 
U-
Cells/well (x1Q-3) 
20 
3 12 25 50 100 
1.0 --k't~+r---':-----'-------_---L 
0.01 
MEF + ConA 
f~ 113100 
Fig. 1 High frequency of L YDlEA-specific IL-CTLp. CTL were 
generated by in vitro interleukin-mediated expansion of in vivo 
activated interleukin-receptive CTLp (IL-CTLp) as outlined in 
Table I. Second-passage mouse embryo fibroblasts (MEF) were 
used as a source of target cells for the 5lCr-release assay. To 
determine the negative or positive reference frequencies, noninfec-
ted MEF were used either in the absence of lectin or with addition 
of 20 jJ.g ml- 1 Con A, respectively. Infected target cells after selec-
tive expression of immediate early genes (IE-MEF) served to 
determine the frequency of IL-CTLp specific for the immediate 
early antigen (L YDIEA) of MCMV. Details ofthe limiting dilution 
assay are given in Table I and details of tbe target cell preparation 
in Table 2. 
to the expression of an antigen on the cell surfaces. This antigen 
is recognized by CTL and was therefore designated lymphocyte-
detected IE antigen (LYDIEA). LYDIEA-specific CTL rep-
resented a distinct subset, separate from those CTL recognizing 
viral structural antigenss. The mere fact, however, that during 
MCMV infection L YDIEA-specific CTL are generated did not 
allow definite conc\usions about the relative significance of the 
immune response to LYDIEA in comparison with the response 
to other antigens specified by MCMV. 
The solution of two experimental problems was aprerequisite 
for attempts to evaluate the significance of LYDIEA. First, in 
viva primed CTL precursors (CTLp) can be detected only after 
c\onal expansion in vitra by testing their cytolytically active 
progeny. This expansion has to be performed in the absence of 
antigen because restimulation in vitra may favour or disfavour 
the growth of CTLp specific for certain antigens and thereby 
cause a distortion of the numerical in viva representation of 
specificities. The expansion of interleukin-receptive CTLp (IL-
CTLp) by interleukin solves this problem as that procedure 
selects cells only on the basis of differentiation20 • 
The second problem arises from the fact that progeny CTL 
are usually detected by their ability to recognize target cells 
carrying the relevant antigens. This recognition requires 
sulficient amounts of antigen to be present at the cell mem-
brane21 • Selective and sulficient expression of L YDIEA can be 
achieveds, but it is not certain in a particular experiment whether 
each of the other viral antigens is also expressed sulficiently. 
Therefore, to detect all IL-CTLp generated during MCMV infec-
tion regardless of their antigen-specificity, the lectin-dependent 
cellular cytotoxicity (LDCC) assay was applied. In this assay 
the T-cell mitogenic lectins concanavalin A (Con A) and 
phytohaemagglutinin (PHA) are used to bypass the requirement 
for specific interaction between CTL and target cells22•23 • The 
highest frequency of IL-CTLp was measured when ConA was 
added at doses of 10-20 J.Lg ml- ' (Table 1). The fact that the 
corresponding frequency in unprimed mice ranged from I in 
70,400 to I in 91,400 Iymphocytes (data not shown) proved that 
the CTL detected in the lectin-dependent cellular cytotoxicity 
(LDCC) assay were derived from in vivo sensitized precursors. 
This condition was then used to assess the total frequency of 
IL-CTLp. 
The results of a representative limiting dilution assay are 
shown in Fig. 1 and those of an independent second experiment 
summarized in. Table 2. The frequency of L YDIEA-specific 
IL-CTLp present in a draining popliteallymph node was found 
to be I in 6,600 Iymphocytes (Fig. I) or I in 6,900 Iymphocytes, 
respectively (Table 2). This determination was carried out on 
target cells that selectively expressed high amounts of IE pro-
teins. The selective transcription of IE genes in target cells was 
achieved by infection in the presence ofthe translation inhibitor 
cyc\oheximide that led to an accumulation of IE RNA. The 
subsequent release from cyc\oheximide and further cultivation 
in the presence of the transcription inhibitor actinomycin D 
then resulted in an enhanced synthesis of IE proteins and 
simultaneously prevented further viral transcriptions.19• 
During noninterrupted (productive) infection, the synthesis 
of IE proteins is followed by the synthesis of so-called early 
proteins and, after viral DNA replication, of late proteins which 
inc\ude the major viral structural proteins 10.24. Among those 
especially the glycoproteins of the virion envelope should con-
tribute significantly to the antigenicity of infected cells. 
Nevertheless, when tested on cells corresponding to the late 
Table 2 IL-CTLp frequencies as determined by antigen-specific or lectin-dependent cellular cytotoxicity 
No. of IL-CTLp 
pe0 061ymphocytes 
Target cell (virus dose; inhibitors) IL-CTLp frequency (95% confidence limits) pMC 
MEF (-; CH-Act.D) 1/166,400 6 (4-8) 0.35 
MEF+ Con A (-; Ch-Act.D) 1/2,700 371 (226-516) 0.27 
JE-MEF (0.05; CH-Act.Q) 1/6,900 146 (97-195) 0.16 
Late-MEF (0.05; -Act.D) 1/11,300 89(60-118) 0.24 
UV-MCMV-MEF (0.05; CH-Act.D) 1/85,300 12 (8-16) 0.35 
UV-MCMV-MEF (0.5; CH-Act.D) 1/44,300 23 (12-33) 0.16 
UV-MCMV-MEF (5; CH-Act.D) 1/14,900 67 (48-86) 0.08 
Second-passage MEF were used as target cells throughout. Infection was performed under centrifugal enhancement conditions34 (800g for 30 mini 
with the indicated virus dose of infection that is given in plaque-forming units (PFU) per cell as determined in a conventional plaque titration 
assay. Tbe centrifugation enhances the efficiency of infection by 20- to 80-fold and thus a virus dose of 0.05 PFU corresponds with an effective 
multi pli city of about 1-4 PFU per cell. At a multiplicity of 100-400 PFU per cell target cells started to disintegrate and therefore the application 
of higher doses was precluded. For the preparation of IE targets and the appropriate controls, infection and 3 h of cultivation were performed in 
the presence of cycI6heximide (CH, 50 jJ.g mI-I). Tbereafter, CH was washed out and actinomycin D (Act.D, 5 jJ.g mI-I) was added. Only for the 
preparation of the late-MEF target, infection was carried out in the absence of CH and viral replication was allowed to proceed for 20 h until 
transcription was stopped by addition of actinomycin D. To test lectin-dependent cytotoxicity, Con A was added during the effector phase at a 
final dose of 20 jJ.g/ml. For mock-infection of MEF, partially purified stock virus (2 x 108 PFU ml- I)20 was diluted witb phosphate-buffered saline 
to a final concentration of I x 107 PFU ml- I and then exposed as an I-mm layer to a lO-min irradiation with a 90 W UV-iI\uminator at 254 nm. 
The distance between specimen surface and ultraviolet-screen was adjusted to give an intensity of 30 J m -2 s - I. To control the effect of irradiation 
on viral protein synthesis35, MEF were infected with the highest dose of virus used in the experiments (5 PFU equivalents per cell) and JE protein 
synthesis was enhanced by inhibitor treatment. Monoclonal antibody 6/58/ I (to be described elsewhere) was then used to detect IE nucJear antigen 
by indirect immunofluorescence. Irradiation of virus for 2.5 min (4,500 J m-2 ) reduced the number of IE antigen positive cells to less than 1% and 
after 5 min of irradiation viral protein synthesis was abolished in all cells. 
©          Nature Publishing Group1984
~N~ATU~R=E~V~O~L~.~31~2~2~2~NO~V~E~M~B~E~R~I~98~4 ____________ ----LETTERSTONATURE------------------------------------~371 
stage of viral replication, the frequency of IL-CTLp was only 
1 in 12,800 Iymphocytes (not depicted in Fig. 1) or 1 in 11,300 
lymphocytes, respectively (Table 2). 
In addition to de novo synthesized antigens, virion proteins 
or glycoproteins inserted into the cell membrane du ring the 
process of penetration can directly account for an antigenicity 
of MCMY-infected cells. This has been demonstrated previously 
by infection of cells in the continuous presence of actinomycin 
D or cycloheximide8• Different treatment, mock-infection with 
UY-inactivated virus, still permits the synthesis of cellular pro-
teins which might be induced by viral structural proteins and 
could also contribute to target formation. This control is there-
fore indicated to discriminate between target antigens induced 
by the IE activity of the viral genome and those antigens whose 
expression does not require IE protein synthesis. When mock-
infection of targets was performed with a dose of ultraviolet-
inactivated virus equivalent to the dose of infectious virus 
applied for preparing the IE target, the frequency was only I 
IL-CTLp in 85,300 Iymphocytes (Table 2). This result proved 
that the high frequency of 1 IL-CTLp in 6,900 Iymphocytes, 
detected with the IE target, was indeed due to the expression 
ofan IE antigen and thus referred to LYDIEA-specific IL-CTLp. 
This conclusion is further confirmed by the finding that in the 
absence of viral genome-induced protein synthesis even a hun-
dred-fold increase in the virus dose did not allow to detect the 
number of IL-CTLp that could be detected with the IE target 
or with the productively infected target (Table 2). 
The total frequency of IL-CTLp in these experiments was 
found to be I in 3,100 Iymphocytes (Fig. I) or 1 in 2,700 
lymphocytes, respectively (Table 2). Hence, based on the deter-
mination of the total IL-CTLp frequency, the L YDIEA-specific 
subset comprised 40-50% of all IL-CTLp generated during 
infection. 
The finding that such a substantial proportion ofthe IL-CTLp 
recognize an antigen expressed during the IE phase of viral 
replication was unexpected because transcription at that stage 
is restricted to only few genes, while extensive transcription 
from the whole genome occurs at later stages 19. 
Three possibilities might explain the high frequency of 
L YDIEA-specific IL-CTLp: First, the primary T cell specificity 
repertoire of BALB/ c mice may already contain a high relative 
number of precursors specific for this antigen. There is no 
approach to test this possibility as limiting dilution experiments 
have revealed an extremely low frequency of primary CTLp 
specific for MCMy20 or herpes simplex virus25 and that is why 
a reliable comparison between partieular antigens is not feasible. 
Second, the expression of antigens may be different in the 
tissues ofthe infected animal than predicted from the productive 
infection of embryonic fibroblasts in vitro. Since in the 
immunocompetent host MCMY does not replicate at the site of 
intraplantar infection, whereas after immunosuppression fibro-
blasts ofthe footpad tissue are productively infected (manuscript 
in preparation), the immune system is involved in terminating 
the in vivo viral replication at an early stage. This could imply 
a preferential sensitization of LYDIEA-specific CTLp and 
explain the high proportion of L YDIEA-specific IL-CTLp in 
the draining lymph node. We are now testing the amount of IE 
gene expression by in situ hybridization using cloned viral DNA 
fragments l9 • 
Third, the IE antigen may be highly immunogenic. Its 
molecular identity has first to be defined in order to evaluate 
this alternative. At present it is known that the expression of 
LYDIEA requires transcription and translation8 and coincides 
with the synthesis of a phosphorylated but not glycosylated 
pro tein of 89,000 apparent relative molecular mass. This protein 
and its post-translational modification products are the 
dominant IE proteins located in the nucleus and cytoplasm of 
the infected cell (G. M. Keil et al., in preparation). Since recogni-
tion by CTL must be considered as a prima fade evidence for 
surface localization of an antigen, the actual relationship 
between these serologically detectable intracellular proteins and 
the antigen LYDIEA requires further analysis. The presence of 
nonglycosylated viral proteins, located predominantly in the 
nucleus and cytoplasm, coincides with the recognition of infec-
ted cells by CTL also in other virus infections such as Epstein-
Barr virus26 , simian virus 4027•28 and influenza virus29- 31 • In this 
context it has been suggested that processed products rather 
than the intact protein may represent the actual antigen31 or 
that the intracellular protein may modify other viral or cellular 
products29 • 
Irrespective of the so far unknown molecular identity of 
LYDIEA, the requirement of IE proteins for the synthesis of 
viral structural proteins during acute infection or after reactiva-
tion from latency raises the possibility of a physiological role 
of LYDIEA-specific CTL in the surveillance of viral latency. 
L YDIEA-specific memory-CTL which are present in latently 
infected mice8 could be activated as soon as IE genes are 
expressed and eliminate recurrently infected cells before the 
assembly of progeny virions. 
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Phorbol ester and diacylglycerol 
mimic growth factors 
in raising cytoplasmic p H 
W. H. Moolenaar, L. G. J. Tertoolen & S. W. de Laat 
Hubrecht Laboratory, International Embryological Institute, 
Uppsalalaan 8, 3584 eT Utrecht, The Netherlands 
There is now good evideoce that cytoplasmic pH (PH;) may have 
an important role in the metabolic activation of quiescent cellsl,z. 
In particular, growth stimulation of mammalian fibroblasts leads 
to a rapid increase in pHi (refs 3-6), due to activation of a Na+ IH+ 
exchanger in the plasma membrane4, and this alkalinization is 
necessary for the initiation of DNA synthesis7• However, the 
mechanism by which mitogens activate the Na+/H+ exchanger to 
raise pHi is not known, although an increase in cytoplasmic free 
Ca2+ (lCaz+Ji) has been postulated as the primary trigger8-lO. We 
